Long-term follow-up of plasma cells in bone marrow and serum free light chains in primary systemic AL amyloidosis

Internal Medicine

Volumn 47, Issue 20, 2008, Pages 1783-1790

  Yoshida, Takuhiro ^a   Matsuda, Masayuki ^a   Katoh, Nagaaki ^a   Tazawa, Ko Ichi ^a   Shimojima, Yasuhiro ^a   Gono, Takahisa ^a   Ishii, Wataru ^a   Nakazawa, Yozo ^a   Sakashita, Kazuo ^a   Koike, Kenichi ^a   Yamada, Toshiyuki ^b   Ikeda, Shu Ichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Jikei University   (Japan)

Author keywords

AL amyloidosis; Chemotherapy; Flow cytometry; Free light chain; Plasma cell

Indexed keywords

ALPHA5 INTEGRIN; CD45 ANTIGEN; CREATININE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN LIGHT CHAIN; M PROTEIN; MELPHALAN; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DISEASE MARKER; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PLASMA CELL; PRIMARY SYSTEMIC AL AMYLOIDOSIS; REMISSION;

ADULT; AGED; AMYLOIDOSIS; ANTIGENS, CD45; BIOLOGICAL MARKERS; BONE MARROW; CASE-CONTROL STUDIES; CHEMOKINE CCL2; CREATININE; DRUG THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; INTEGRIN ALPHA5; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUSCLE PROTEINS; PLASMA CELLS; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 56349091351     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0966     Document Type: Article

References (24)

1. Buxbaum J. The amyloidoses. In: Rheumatology. 2nd ed. Klippel JH, Dieppe PA, Eds. Mosby, London, 1998: 8.27.1-10.
2. Kyle RA, Gertz MA. Primary systemic amyloidosis. Clinical and laboratory features in 474 cases. Semin Hematol 32: 45-59, 1995.
3. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 97: 2900-2902, 2001.
4. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 47: 673-680, 2001.
5. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 48: 1437-1444, 2002.
6. Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 119: 274-278, 2003.
7. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 122: 78-84, 2003.
8. Matsuda M, Gono T, Shimojima Y, Hoshii Y, Ikeda S. Phenotypic analysis of plasma cells in bone marrow using flow cytometry in AL amyloidosis. Amyloid: J. Protein Folding Disord 10: 110-116, 2003.
9. Matsuda M, Gono T, Shimojima Y, Sakashita K, Koike K, Ikeda S. Evaluation of intensive chemotherapy in primary systemic AL amyloidosis. Usefulness of flow cytometric analysis of plasma cells in the bone marrow. Amyloid: J. Protein Folding Disord 10: 250-256, 2003.
10. Shimojima Y, Matsuda M, Gono T, et al. Correlation between serum levels of free light chain and phenotype of plasma cells in bone marrow in primary AL amyloidosis. Amyloid: J. Protein Folding Disord 12: 33-40, 2005.
11. Hoshii Y, Setoguchi M, Iwata T, et al. Useful polyclonal antibodies against synthetic peptides corresponding to immunoglobulin light chain constant region for immunohistochemical detection of immunoglobulin light chain amyloidosis. Pathol Int 51: 264-270, 2001.
12. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma, and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121: 749-757, 2003.
13. Gono T, Matsuda M, Dohi N, et al. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Intern Med 42: 72-77, 2003.
14. Gono T, Matsuda M, Shimojima Y, et al. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. Amyloid: J. Protein Folding Disord 11: 245-256, 2004.
15. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 103: 2936-2938, 2004.
16. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 99: 4276-4282, 2002.
17. Kawano MM, Huang N, Harada H, et al. Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood 82: 564-570, 1993.
18. Huang N, Kawano MM, Harada H, et al. Heterogeneous expression of a novel MPC-1 antigen on myeloma cells. Possible involvement of MPC-1 antigen in the adhesion of mature myeloma cells to bone marrow stromal cells. Blood 82: 3721-3729, 1993.
19. Kawano MM, Mahmoud MS, Huang N, et al. High proportions of VLA-5-immature myeloma cells correlated well with poor response to treatment in multiple myeloma. Br J Haematol 91: 860-864, 1995.
20. Mahmoud MS, Ishikawa H, Fujii R, Kawano MM. Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6. Blood 92: 3887-3897, 1998.
21. Ishikawa H, Mahmoud MS, Fujii R, Abroun S, Kawano MM. Proliferation of immature myeloma cells by interleukin-6 is associated with CD45 expression in human multiple myeloma. Leuk Lymphoma 39: 51-55, 2000.
22. Clark RJ, Katzmann JA, Abraham RS, Lymp JF, Kyle RA, Bradwell AR. Detection of monoclonal free light chains by nephelometry: normal ranges and relative sensitivity. Clin Chem 47: a27, 2001.
23. Matsuda M, Yamada T, Gono T, et al. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis. Intern Med 44: 428-433, 2005.
24. + subpopulations that can proliferate in response to IL-6 in human myelomas. Br J Haematol 105: 131-140, 1999.